Equity Profile

SRPT

Sarepta Therapeutics, Inc.

Health CareBiotechnology$2.0B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD)....

Key Metrics to Watch

DMD Treatment Progress

Updates on the development and approval status of treatments for Duchenne muscular dystrophy are crucial for investor confidence.

Progress updates expected.

Research and Development Spending

Investors will be keen to see how much is being invested in R&D, as this reflects the company's commitment to innovation.

$X million.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRPT Q2-2026 Earnings Preview

Context

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD). With a market cap of $2 billion, its advancements in gene therapy are significant in the health care sector, especially as demand for specialized treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+1856.93%

Avg Stock Reaction

-2.62%

Last Quarter Recap

In Q1-2026, Sarepta reported an impressive earnings surprise with an EPS of $3.16, significantly exceeding expectations. This positive performance led to a 5.69% increase in stock price the following day.

Management Promises & Guidance

Focus on advancing DMD therapies.
Commitment to increasing R&D investments.
Plans to explore new partnerships for growth.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the recent strong performance and the potential for further positive news. However, uncertainty remains regarding the sustainability of growth.

Bull Case

If Sarepta continues to show strong progress in its DMD treatments and secures new partnerships, it could lead to significant stock appreciation.

Bear Case

On the other hand, any delays in product development or disappointing updates could lead to a sharp decline in investor confidence.

Key Metrics to Watch

DMD Treatment Progress

Progress updates expected.

Updates on the development and approval status of treatments for Duchenne muscular dystrophy are crucial for investor confidence.

Research and Development Spending

$X million.

Investors will be keen to see how much is being invested in R&D, as this reflects the company's commitment to innovation.

Partnership Announcements

Potential new partnerships.

New collaborations can enhance growth prospects and validate the company's technology.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific progress has been made in the development of DMD therapies?

This will directly impact investor sentiment and the stock price, as successful advancements could validate the company's strategy.

How much is being allocated to R&D this quarter?

Investors will want to know if the company is investing adequately in future growth, which can affect long-term performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Sarepta's DMD therapies to gain traction, given recent positive trial results that have not been fully factored into forecasts.

Supporting Evidence

Recent earnings showed a substantial surprise, indicating stronger-than-expected performance.

Options pricing suggests a moderate move, which may not reflect the potential upside if positive news is announced.

The company's historical performance indicates a strong ability to exceed expectations.

Key Risk

If the DMD treatment updates show significant advancements, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to maintain momentum in its drug development efforts.

Bull Confirmed If

Demonstrating significant progress in DMD treatment development, with updates indicating successful trials.

Bear Confirmed If

Any indication of delays or setbacks in the DMD treatment pipeline.

Pre-Earnings Positioning

Options Market

Implied Move

±4.61%

Historical Avg

±5.3%

In line with history

The options market is pricing in a moderate move around the earnings report, suggesting some uncertainty but not extreme volatility.

Options are pricing ±4.6% while SRPT has averaged ±5.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.7%

30d HV

50.4%

Calls (88K)P/C Ratio: 0.27Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sarepta beats expectations, history suggests a potential average one-day move of +0.82%, confirming bullish sentiment.

In-Line / Cautious

An in-line report could lead to a muted reaction as investors weigh management's commentary on future prospects.

Miss

If the company misses expectations, history indicates an average one-day decline of -12.94%, which could significantly impact investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of DMD therapies and any trial results.
2Updates on R&D spending and future investment plans.
3Information on potential new partnerships or collaborations.
4Management's outlook on market conditions and competitive landscape.
5Any commentary on regulatory interactions or approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly genetic disorders like Duchenne muscular dystrophy (DMD)....

Key Metrics to Watch

DMD Treatment Progress

Updates on the development and approval status of treatments for Duchenne muscular dystrophy are crucial for investor confidence.

Progress updates expected.

Research and Development Spending

Investors will be keen to see how much is being invested in R&D, as this reflects the company's commitment to innovation.

$X million.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SRPT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+1856.93%

Avg Stock Reaction

-2.62%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing DMD therapies.
Commitment to increasing R&D investments.
Plans to explore new partnerships for growth.

Expectations

Wall Street Expectations

Bull Case

If Sarepta continues to show strong progress in its DMD treatments and secures new partnerships, it could lead to significant stock appreciation.

Bear Case

On the other hand, any delays in product development or disappointing updates could lead to a sharp decline in investor confidence.

Key Metrics to Watch

DMD Treatment Progress

Progress updates expected.

Updates on the development and approval status of treatments for Duchenne muscular dystrophy are crucial for investor confidence.

Research and Development Spending

$X million.

Investors will be keen to see how much is being invested in R&D, as this reflects the company's commitment to innovation.

Partnership Announcements

Potential new partnerships.

New collaborations can enhance growth prospects and validate the company's technology.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific progress has been made in the development of DMD therapies?

This will directly impact investor sentiment and the stock price, as successful advancements could validate the company's strategy.

How much is being allocated to R&D this quarter?

Investors will want to know if the company is investing adequately in future growth, which can affect long-term performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Sarepta's DMD therapies to gain traction, given recent positive trial results that have not been fully factored into forecasts.

Supporting Evidence

Recent earnings showed a substantial surprise, indicating stronger-than-expected performance.

Options pricing suggests a moderate move, which may not reflect the potential upside if positive news is announced.

The company's historical performance indicates a strong ability to exceed expectations.

Key Risk

If the DMD treatment updates show significant advancements, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to maintain momentum in its drug development efforts.

Bull Confirmed If

Demonstrating significant progress in DMD treatment development, with updates indicating successful trials.

Bear Confirmed If

Any indication of delays or setbacks in the DMD treatment pipeline.

Pre-Earnings Positioning

Options Market

Implied Move

±4.61%

Historical Avg

±5.3%

In line with history

The options market is pricing in a moderate move around the earnings report, suggesting some uncertainty but not extreme volatility.

Options are pricing ±4.6% while SRPT has averaged ±5.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.7%

30d HV

50.4%

Calls (88K)P/C Ratio: 0.27Puts (54K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Sarepta beats expectations, history suggests a potential average one-day move of +0.82%, confirming bullish sentiment.

In-Line / Cautious

An in-line report could lead to a muted reaction as investors weigh management's commentary on future prospects.

Miss

If the company misses expectations, history indicates an average one-day decline of -12.94%, which could significantly impact investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the progress of DMD therapies and any trial results.
2Updates on R&D spending and future investment plans.
3Information on potential new partnerships or collaborations.
4Management's outlook on market conditions and competitive landscape.
5Any commentary on regulatory interactions or approvals.